The present disclosure provides methods for treating
pulmonary hypertension (PH) in a patient in need thereof, comprising administering via a
dry powder inhaler (DPI) to the patient, during an administration period, a compound of Formula (I), (I), or an
enantiomer,
diastereomer, or a pharmaceutically acceptable salt thereof, wherein R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. In embodiments, during the administration period, the compound of Formula (I), or an
enantiomer,
diastereomer, or a pharmaceutically acceptable salt thereof, is administered at a starting
dose comprising about 80 μg to 160 μg once daily in a single dosing session, and the starting
dose is titrated during the
titration period to a
maximum tolerated dose (MTD) of about 1280 µg or less. In embodiments, the administration period comprises a maintenance period, and the MTD is administered to the patient during the maintenance period. In embodiments, during the administration period, a
dose of about 700-1300 µg of the compound of Formula (I), or
enantiomer,
diastereomer, or a pharmaceutically acceptable salt thereof, is administered once daily in a single dosing session to the patient.